Cyclacel Pharmaceuticals, Inc. (CYCC)
Stock Price:
$3.20 USD
-0.22 (-6.43%)
Updated Oct 30, 2020 3:01 PM EDT - Market open
Key Info
| Market Cap |
15.56M |
| Revenue (ttm) |
150,000 |
| Net Income (ttm) |
-7.79M |
| Shares Out |
4.86M |
| EPS (ttm) |
-4.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$3.20 |
| Previous Close |
$3.42 |
| Change ($) |
-0.22 |
| Change (%) |
-6.43% |
| Day's Open |
3.37 |
| Day's Range |
3.20 - 3.40 |
| Day's Volume |
39,024 |
| 52-Week Range |
3.12 - 19.60 |
More Stats
| Market Cap |
15.56M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.86M |
| Float |
4.82M |
| EPS (basic) |
-7.06 |
| EPS (diluted) |
-4.85 |
| FCF / Share |
-2.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
53,515 |
| Short Ratio |
0.19 |
| Short % of Float |
1.11% |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
103.76 |
| PB Ratio |
0.59 |
| Revenue |
150,000 |
| Operating Income |
-10.04M |
| Net Income |
-7.79M |
| Free Cash Flow |
-7.78M |
| Net Cash |
24.26M |
| Net Cash / Share |
4.99 |
| Gross Margin |
-3,105.33% |
| Operating Margin |
-6,692.00% |
| Profit Margin |
n/a |
| FCF Margin |
-5,188.67% |
| ROA |
-25.80% |
| ROE |
-35.88% |
| ROIC |
-286.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.33*
(566.56% upside)
Low
18.0
Current: $3.20
High
24.0
Target: 21.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | 0.15 | - | 0.84 | 1.94 | 1.73 | 1.08 | 0.07 | - | 0.11 |
| Revenue Growth | - | - | - | -56.64% | 12.11% | 59.96% | 1471.01% | - | - | - |
| Gross Profit | - | 0.15 | - | 0.84 | 1.94 | 1.73 | 1.08 | 0.07 | - | 0.11 |
| Operating Income | -9.68 | -9.55 | -9.49 | -14.15 | -16.17 | -22.44 | -17.97 | -15.10 | -15.75 | -15.14 |
| Net Income | -7.83 | -7.29 | -7.47 | -11.79 | -14.34 | -19.39 | -10.15 | -13.19 | -15.24 | -16.02 |
| Shares Outstanding | 0.82 | 0.60 | 0.38 | 0.17 | 0.14 | 0.09 | 0.06 | 0.03 | 0.03 | 0.02 |
| Earnings Per Share | -9.80 | -12.40 | -39.00 | -70.00 | -107.20 | -213.61 | -307.21 | -403.22 | -532.82 | -873.64 |
| Operating Cash Flow | -9.45 | -6.70 | -7.48 | -10.08 | -14.46 | -18.70 | -18.20 | -12.04 | -13.98 | -16.04 |
| Capital Expenditures | 0.03 | -0.04 | -0.01 | 0.01 | -0.03 | -0.31 | -0.21 | 0.05 | - | 0.03 |
| Free Cash Flow | -9.42 | -6.74 | -7.49 | -10.07 | -14.49 | -19.01 | -18.41 | -11.99 | -13.98 | -16.01 |
| Cash & Equivalents | 11.89 | 17.50 | 23.91 | 16.52 | 20.44 | 24.19 | 31.15 | 16.41 | 24.45 | 29.50 |
| Total Debt | 1.19 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 10.69 | 17.50 | 23.91 | 16.52 | 20.44 | 24.19 | 31.15 | 16.41 | 24.45 | 29.50 |
| Assets | 15.31 | 19.82 | 26.00 | 19.66 | 24.76 | 29.39 | 35.52 | 19.35 | 26.00 | 31.46 |
| Liabilities | 3.61 | 4.55 | 4.24 | 5.39 | 5.93 | 7.70 | 7.50 | 9.34 | 6.50 | 6.54 |
| Book Value | 11.70 | 15.27 | 21.77 | 14.27 | 18.84 | 21.69 | 28.02 | 10.02 | 19.50 | 24.92 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cyclacel Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Spiro Rombotis |
Stock Information
| Ticker Symbol |
CYCC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CYCC |
Description
Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.